West Coast Bio Lab LLC

West Coast Bio Lab LLC was paid $2.12M by Medicaid between Oct 2022 and Dec 2024, across 15 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 24% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#147 of 561

Median peer was paid$222K

This provider vs. median9.6×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	8,923	$335K
2023	22,641	$854K
2024incomplete	22,148	$936K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	24%	7,676	2,504	$518K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	22%	5,327	1,577	$475K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	14%	10,398	4,641	$298K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	14%	3,372	998	$290K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	13%	11,859	3,889	$273K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	5.4%	6,071	2,043	$115K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.8%	5,208	1,670	$80K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	3.2%	3,360	979	$68K
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	<1%	258	157	$5K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	87	66	$967.92
87634		<1%	19	19	$247.08
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	30	29	$87.75

3 more codes

80061	Lipid panel	<1%	12	$69.24
80053	Comprehensive metabolic panel	<1%	15	$64.33
36415	Collection of venous blood by venipuncture	0%	20	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKHAN, RAIHAAN (PRESIDENT)